Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists

被引:12
|
作者
Tosh, Dilip K. [1 ]
Ciancetta, Antonella [1 ]
Mannes, Philip [1 ]
Warnick, Eugene [1 ]
Janowsky, Aaron [2 ,3 ,4 ]
Eshleman, Amy J. [2 ,3 ,4 ]
Gizewski, Elizabeth [5 ]
Brust, Tarsis F. [6 ,7 ]
Bohn, Laura M. [6 ,7 ]
Auchampach, John A. [5 ]
Gao, Zhan-Guo [1 ]
Jacobson, Kenneth A. [1 ]
机构
[1] NIDDK, Mol Recognit Sect, Lab Bioorgan Chem, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA
[2] Oregon Hlth & Sci Univ, VA Portland Hlth Care Syst, Res Serv R&D 22, 3710 SW US Vet Hosp Blvd, Portland, OR 97239 USA
[3] Oregon Hlth & Sci Univ, Dept Psychiat, 3710 SW US Vet Hosp Blvd, Portland, OR 97239 USA
[4] Oregon Hlth & Sci Univ, Dept Behav Neurosci, 3710 SW US Vet Hosp Blvd, Portland, OR 97239 USA
[5] Med Coll Wisconsin, Dept Pharmacol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA
[6] Scripps Res Inst, Dept Mol Med, 130 Scripps Way, Jupiter, FL 33458 USA
[7] Scripps Res Inst, Dept Neurosci, 130 Scripps Way, Jupiter, FL 33458 USA
来源
ACS OMEGA | 2018年 / 3卷 / 10期
关键词
CHRONIC NEUROPATHIC PAIN; 18 KDA TSPO; INDUCED CONSTIPATION; PROTEIN; LIGANDS; BINDING; POTENT; EFFICACY; DESIGN; CANCER;
D O I
10.1021/acsomega.8b01237
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
While screening off-target effects of rigid (N)-methanocarba-adenosine 5'-methylamides as A(3) adenosine receptor (AR) agonists, we discovered mu M binding hits at the d-opioid receptor (DOR) and translocator protein (TSPO). In an effort to increase OR and decrease AR affinity by structure activity analysis of this series, antagonist activity at kappa-(K)OR appeared in 5'-esters (ethyl 24 and propyl 30), which retained TSPO interaction (mu M). 7-Deaza modification of C2-(arylethynyl)-5'-esters but not 4'-truncation enhanced KOR affinity (MRS7299 28 and 29, K-1 approximate to 40 nM), revealed mu-OR and DOR binding, and reduced AR affinity. Molecular docking and dynamics simulations located a putative KOR binding mode consistent with the observed affinities, placing C7 in a hydrophobic region. 3-Deaza modification permitted TSPO but not OR binding, and 1-deaza was permissive to both; ribose-restored analogues were inactive at both. Thus, we have repurposed a known AR nucleoside scaffold for OR antagonism, with a detailed hypothesis for KOR recognition.
引用
收藏
页码:12658 / 12678
页数:21
相关论文
共 50 条
  • [21] A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity
    Spinaci, Andrea
    Buccioni, Michela
    Dal Ben, Diego
    Maggi, Federica
    Marucci, Gabriella
    Francucci, Beatrice
    Santoni, Giorgio
    Lambertucci, Catia
    Volpini, Rosaria
    PHARMACEUTICALS, 2022, 15 (02)
  • [22] Adenosine receptor agonists
    Jacobson, MA
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2002, 12 (04) : 489 - 501
  • [23] Effects of adenosine receptor agonists and antagonists on pentylenetetrazole-induced amnesia
    Homayoun, H
    Khavandgar, S
    Zarrindast, MR
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 430 (2-3) : 289 - 294
  • [24] Effect of adenosine receptor agonists and antagonists on the expression of opiate withdrawal in rats
    Salem, A
    Hope, W
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1997, 57 (04) : 671 - 679
  • [25] DIFFERENT INFLUENCES OF ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS ON MORPHINE ANTINOCICEPTION IN MICE
    ZARRINDAST, MR
    NIKFAR, S
    GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1994, 25 (01): : 139 - 142
  • [26] DIFFERENTIAL BINDING-PROPERTIES OF ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS IN BRAIN
    MARANGOS, PJ
    PATEL, J
    MARTINO, AM
    DILLI, M
    BOULENGER, JP
    JOURNAL OF NEUROCHEMISTRY, 1983, 41 (02) : 367 - 374
  • [27] EFFECTS OF ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS ON PHYSOSTIGMINE-INDUCED YAWNING
    ZARRINDAST, MR
    ADELI, R
    HOSSEINISEMNANI, S
    SHARIFZADEH, M
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 276 (1-2) : 3 - 7
  • [28] Differences in binding of epoxymorphinan agonists and antagonists to structural models of the opioid receptor
    Strahs, D
    Guarnieri, F
    Weinstein, H
    BIOPHYSICAL JOURNAL, 1997, 72 (02) : WP428 - WP428
  • [29] The role of opioid receptor agonists and antagonists in the treatment of Parkinson’s disease
    I. G. Silkis
    Neurochemical Journal, 2007, 1 : 281 - 287
  • [30] Interaction of μ-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice
    Kögel, B
    Christoph, T
    Strassburger, W
    Friderichs, E
    EUROPEAN JOURNAL OF PAIN, 2005, 9 (05) : 599 - 611